Vect-Horus, a Marseille, France-based biotech company that designs and develops vectors that enable therapeutic molecules or imaging agents to be delivered to key organs, closed its Series D funding.
The first round, held in September 2020, raised €6.7m and a second round in December 2020 added €5.3m from private investors, bringing the total amount raised in these two rounds to €12m.
The company intends to use the funds to pursue its programs, focusing on identifying new vectors, developing theragnostic (therapeutic and diagnostic) agents in a clinical setting and validating its technology for delivering therapeutic antibodies and nucleic acids.
Led by Alexandre Tokay, Chairman, Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumours. The company combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (first and foremost the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder.